抗体鸡尾酒疗法TATX-03 PolyTope治疗COVID-19,临床前数据显示100%有效

2021-02-20 Allan MedSci原创

制药公司ImmunoPrecise近日公布了初步临床前数据,结果显示,专门针对SARS-CoV-2病毒的TATX-03 PolyTope抗体鸡尾酒疗法在仓鼠中能够100%清除病毒。

制药公司ImmunoPrecise近日公布了初步临床前数据,结果显示,专门针对SARS-CoV-2病毒的TATX-03 PolyTope抗体鸡尾酒疗法在仓鼠中能够100%清除病毒。

临床前研究的结果表明,TATX-03 PolyTope抗体鸡尾酒疗法在预防和治疗SARS-CoV-2感染方面均提供强大的抗病毒作用。TATX-03 PolyTope抗体鸡尾酒疗法能够识别多种SARS-CoV-2刺突蛋白,具有防止病毒突变逃逸的潜力。

TATX-03 PolyTope抗体鸡尾酒疗法以单剂的形式施用给感染了SARS-CoV-2变体的仓鼠。研究表明,感染后第4天,抗体鸡尾酒疗法可以完全清除具有复制能力的病毒。此外,研究表明,病毒感染后3天,在100%的仓鼠喉咙中检测不到病毒。

TATX-03 PolyTope抗体鸡尾酒疗法也可以在预防性环境中可预防SARS-CoV-2感染。在用SARS-CoV-2变体感染仓鼠之前24小时施用单剂TATX-03 PolyTope抗体混合物,可导致病毒滴度的降低。

 

原始出处:

https://www.firstwordpharma.com/node/1802521?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797310, encodeId=ba431e97310ac, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Jul 16 22:24:09 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728831, encodeId=27091e28831e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 24 16:24:09 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543016, encodeId=8ec51543016fc, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Mon Feb 22 12:24:09 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574832, encodeId=647715e48326f, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Mon Feb 22 12:24:09 CST 2021, time=2021-02-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797310, encodeId=ba431e97310ac, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Jul 16 22:24:09 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728831, encodeId=27091e28831e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 24 16:24:09 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543016, encodeId=8ec51543016fc, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Mon Feb 22 12:24:09 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574832, encodeId=647715e48326f, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Mon Feb 22 12:24:09 CST 2021, time=2021-02-22, status=1, ipAttribution=)]
    2021-10-24 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797310, encodeId=ba431e97310ac, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Jul 16 22:24:09 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728831, encodeId=27091e28831e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 24 16:24:09 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543016, encodeId=8ec51543016fc, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Mon Feb 22 12:24:09 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574832, encodeId=647715e48326f, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Mon Feb 22 12:24:09 CST 2021, time=2021-02-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797310, encodeId=ba431e97310ac, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Jul 16 22:24:09 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728831, encodeId=27091e28831e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 24 16:24:09 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543016, encodeId=8ec51543016fc, content=<a href='/topic/show?id=f187102958c1' target=_blank style='color:#2F92EE;'>#鸡尾酒疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102958, encryptionId=f187102958c1, topicName=鸡尾酒疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09513514566, createdName=12498768m17(暂无昵称), createdTime=Mon Feb 22 12:24:09 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574832, encodeId=647715e48326f, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Mon Feb 22 12:24:09 CST 2021, time=2021-02-22, status=1, ipAttribution=)]
    2021-02-22 qblt

相关资讯

病毒RNA聚合酶抑制剂AT-527治疗COVID-19,Chugai制药公司将负责日本的开发和销售

日本Chugai制药株式会社今天宣布,它与罗氏公司达成了一项许可协议,以在日本开发和销售新型口服抗COVID-19候选药物AT-527。

Thorax:白介素抑制剂治疗COVID-19的疗效分析

前瞻性研究中tocilizumab治疗与较低的死亡率相关,但对于其他结局尚无定论。目前尚无证据证明anakinra、sarilumab或siltuximab在COVID-19治疗中的疗效。

NHS将为COVID-19患者提供Tocilizumab

英国政府宣布,在发现Tocilizumab可降低COVID-19患者的死亡风险后,将向成千上万的NHS患者提Tocilizumab。在RECOVERY试验中,Tocilizumab显著降低了死亡风险,

英国批准Aplidin(plitidepsin)治疗COVID-19的III期临床试验

Aplidin(plitidepsin)通过阻断人类细胞中存在的eEF1A蛋白发挥作用,SARS-CoV-2使用它来复制和感染其他细胞。

JAHA:院前抗凝治疗是COVID-19潜在的保护因素

与住院期间开始AC治疗相比,住院之前开始AC治疗可使患者获得更好的预后。在疾病的早期阶段采用AC治疗可以更好地预防COVID-19相关的凝血疾病、内皮功能紊乱和患者预后。

拓展阅读

新药进展:可预防新冠病毒!阿斯利康长效抗体鸡尾酒疗法获FDA紧急使用授权

根据FDA公告显示,该产品仅被授权用于那些目前未感染SARS-CoV-2病毒和近期未暴露于感染SARS-CoV-2病毒环境的个体。

再生元“抗体鸡尾酒疗法”获批紧急使用授权,将免费供给30万名患者

美国FDA官网显示,其向再生元的REGN-COV2(中和抗体“鸡尾酒”疗法)颁发了紧急授权使用(EUA)。casirivimab和imdevimab可以一起给药,用于治疗有发展